

Turkish Journal of Endocrinology and Metabolism

JOURNAL OF THE SOCIETY OF ENDOCRINOLOGY AND METABOLISM OF TURKEY

EDITORIAL

Dear esteemed readers of TurkJEM Family,

For this issue I will focus on the frontier that digital industry offers for medicine with a special focus on diabetes. Ever-growing technology sectors fruit of digital technology provides different inventions to the benefit of diabetes and metabolism disorders are becoming more and more popular. Digital technologies are the new face of health sector and it's absolutely incumbent that organizations get onboard. Digital interventions for Type 2 diabetes mellitus are universally used. Research findings show that vulnerable people with Type 2 diabetes are unprepared to exhaust digital capabilities. This could be due to two different factors; digital technology not being user friendly and training need of patients. Whatever the cause digital journey started for diabetes patients. Two thirds of adults owning a smartphone and average smartphone owner checks their phone every 6.5 minutes. Management of diabetes requiring regular checks of blood glucose and diet management; applications that allow the patient to keep track of blood glucose measurement are becoming wide spread. Insulin related applications are aimed at people with type 1 diabetes calculating insulin need based on six different factors. Carbohydrate and calorie based applications are food and drink databases providing nutritional information.

The reality is a conservative approach of to actually implementing most of these new digital tools. Experts ask for providers to participate in the process to be part of the change process. We should not forget that all digital improvements are made to improve patient's health and comfort. Beyond well-structured applications digital tools are used for the training of people with diabetes to self-manage their disease. There are internet portals and websites available for such purposes. Besides the positive aspects of digital applications helping patients, there is still need for effectiveness and cost benefit of digital tools in improving diabetes related outcomes. For now we can only declare that the digital journey has started for patients and time will show new areas to exhaust in the patients quality of life.

In our fall issue we have the following paper contributions:

Ischemia modified albumin levels in patients with diabetic nephropathy; Paraoxonase 1 activity and its polymorphism in type 2 diabetic nephropathy; Nodular thyroid disease and papillary thyroid carcinoma in functional pituitary adenomas; Relationship of decreased circulating apelin levels with growth hormone, insulin-like growth factor, carotid intima-media thickness, and epicardial fat thickness in acromegaly; Relation of 18F-FDG PET/CT positivity with tumor cytopathology, galectin-3, PTEN, Ki-67 and NIS expressions in thyroid nodules; Use of biphasic insulin aspart 30 in type 2 diabetes treatment: Expert panel recommendations; Two cases of bullous pemphigoid induced by vildagliptin; A case of thyroid hemiagenesis: An exceptional case; Severe lipodystrophy and gynecomastia in a male patient on lopinavir-based second-line antiretroviral therapy; Dapagliflozin induced vulvovaginitis in an atopic patient with type 2 diabetes mellitus.

I wish all the TurkJEM Family a happy fall season.

With my best regards,

Nilgün Başkal MD Editor-in-Chief